

Alzheimer's A β 42/40 with p-tau217 Testing is Available at LifeLabs

Dear valued Health Care Provider,

LifeLabs is proud to support you in assessing your patient's risk of developing Alzheimer's disease (AD) by offering one of the industry's most comprehensive portfolios of blood-based biomarker tests. Our suite of AD tests includes the A β 42/40 ratio and p-tau217 Evaluation panel, the standalone p-tau217, and the A β 42/40 ratio (see *Alzheimer's Disease – LifeLabs*).

Importantly, the LifeLabs A β 42/40 and p-tau217 Evaluation panel is a CLIA-cleared laboratory-developed test and is distinct from the Fujirebio Lumipulse p-tau217/A β 42 assay. As such, LifeLabs' Alzheimer's tests are not affected by the current quality hold associated with the Fujirebio Lumipulse p-tau217/A β 42 assay (see *Trouble with Fujirebio's FDA-Cleared Blood Test? Or a Lousy Lot? | ALZFORUM*) and continue to provide reliable risk stratification.

The LifeLabs' A β 42/40 ratio and p-tau217 Evaluation panel estimates the likelihood of amyloid PET positivity (categorized as low, indeterminate, or high). Performance characteristics include:

- Sensitivity: 91%
- Specificity: 91%
- Positive predictive value: 87% (at an estimated disease prevalence of ~46%)
- Negative predictive value: 91% (at an estimated disease prevalence of ~46%)

These clinically proven, established assays demonstrate strong alignment with patients' clinical presentations.

What This Means for You

Testing for the A β 42/40 ratio with p-tau217, using the Evaluation panel, remains available through LifeLabs. Test requests can be submitted using the Alzheimer's custom requisition form (*LifeLabs-Alzheimers-ON-Requisition-Ver-003-June-10-2025.pdf*) or a standard OHIP laboratory requisition form by writing the test names in the "Other Tests" section.

When used for patients with mild cognitive impairment (MCI), this panel provides accurate risk stratification and meets or exceeds the Alzheimer's CEO Initiative (CEOi) performance standards for confirmatory blood-based biomarkers (see *BBM Performance Standards – CEO Initiative on Alzheimer's*).

Thank you for your continued trust in our laboratory services. We remain committed to supporting your Alzheimer's testing needs with high-quality, evidence-based insights and care.

If you have any questions, please contact the LifeLabs Customer Care Centre at 1-877-849-3637.

Sincerely,

LifeLabs

References

[Alzheimers Disease – LifeLabs](#)

[Trouble with Fujirebio's FDA-Cleared Blood Test? Or a Lousy Lot? | ALZFORUM](#)

[LifeLabs-Alzheimers-ON-Requisition-Ver-003-June-10-2025.pdf](#)

[BBM Performance Standards - CEO Initiative on Alzheimers](#)

Alzheimer's A β 42/40 with p-tau217 Testing is Available at LifeLabs

Dear valued Health Care Provider,

LifeLabs is proud to support you in assessing your patient's risk of developing Alzheimer's disease (AD) by offering one of the industry's most comprehensive portfolios of blood-based biomarker tests. Our suite of AD tests includes the A β 42/40 ratio and p-tau217 Evaluation panel, the standalone p-tau217, and the A β 42/40 ratio (see *Alzheimer's Disease – LifeLabs*).

Importantly, the LifeLabs A β 42/40 and p-tau217 Evaluation panel is a CLIA-cleared laboratory-developed test and is distinct from the Fujirebio Lumipulse p-tau217/A β 42 assay. As such, LifeLabs' Alzheimer's tests are not affected by the current quality hold associated with the Fujirebio Lumipulse p-tau217/A β 42 assay (see *Trouble with Fujirebio's FDA-Cleared Blood Test? Or a Lousy Lot? | ALZFORUM*) and continue to provide reliable risk stratification. The LifeLabs' A β 42/40 ratio and p-tau217 Evaluation panel estimates the likelihood of amyloid PET positivity (categorized as low, indeterminate, or high). Performance characteristics include:

- Sensitivity: 91%
- Specificity: 91%
- Positive predictive value: 87% (at an estimated disease prevalence of ~46%)
- Negative predictive value: 91% (at an estimated disease prevalence of ~46%)

These clinically-proven, established assays demonstrate strong alignment with patients' clinical presentations.

What This Means for You

Testing for the A β 42/40 ratio with p-tau217, using the Evaluation panel, remains available through LifeLabs. Test requests can be submitted using the Alzheimer's custom requisition form (*LifeLabs-Alzheimers-ON-Requisition-Ver-003-June-10-2025.pdf*) or a standard OHIP laboratory requisition form by writing the test names in the "Other Tests" section.

When used for patients with mild cognitive impairment (MCI), this panel provides accurate risk stratification and meets or exceeds the Alzheimer's CEO Initiative (CEOi) performance standards for confirmatory blood-based biomarkers (see *BBM Performance Standards – CEO Initiative on Alzheimer's*).

Thank you for your continued trust in our laboratory services. We remain committed to supporting your Alzheimer's testing needs with high-quality, evidence-based insights and care.

If you have any questions, please contact the LifeLabs Customer Care Centre at 1-877-849-3637.

Sincerely,

LifeLabs